Fennec Pharmaceuticals Inc.
FENC Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$10.08
KIRA · Stoqly’s AI analyst, in plain words
- Fennec Pharmaceuticals Inc. had $44.6M of revenue in fiscal 2025, down 6.1% on the year before. Over five years, revenue changed +194.9% a year on average.
- Its operating margin was −14.1%, down 19.5 pts: of every 100 in sales, about −14 is left after running the business.
- Fennec Pharmaceuticals Inc. lost $9.7M in fiscal 2025.
Market cap
$367M
P/E
—
Revenue
$44.6M
Net income
−$9.7M
Free cash flow
—
Operating margin
−14.1%
Fennec Pharmaceuticals Inc. in 30 seconds · fiscal 2025
Are sales growing?
−6.1%
No. Sales fell 6.1% last year.
Does it make a profit?
−21.8%
No. It lost money last year.
How healthy are the accounts?
0 / 7
Weak. It passes 0 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Fennec Pharmaceuticals Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- FENNEC PHARMACEUTICALS INC.
- CIK
- 0001211583
Fennec Pharmaceuticals Inc. · FENC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $1.5M | $21.3M | $47.5M | $44.6M |
| Revenue growth | — | — | 1,284.5% | 123.7% | −6.1% |
| Net interest income | — | $0.2M | $0.4M | — | — |
| Gross margin | — | 94.4% | 94.1% | — | — |
| Operating margin | — | −1,471.6% | −60.1% | 5.4% | −14.1% |
| Net income | −$17.3M | −$23.7M | −$16.0M | −$0.4M | −$9.7M |
| Net margin | — | −1,544.9% | −75.5% | −0.9% | −21.8% |
| Diluted EPS | −$0.67 | −$0.90 | −$0.60 | −$0.02 | −$0.34 |
| Cash | |||||
| Cash from operations | −$14.2M | −$18.1M | −$17.1M | $27.0M | −$12.5M |
| Share count change | 109,630.0% | 1.0% | 1.1% | 2.7% | 4.7% |
| Debt and strength | |||||
| Cash and short-term investments | $21.1M | $23.8M | $13.3M | $26.6M | $36.8M |
| Debt incl. finance leases | $5.0M | $24.9M | $30.9M | $19.3M | — |
| Shareholders' equity | $15.8M | −$2.6M | −$11.6M | −$5.9M | $35.5M |
| Current ratio | 13.5x | 5.8x | 3.6x | 6.4x | 6.4x |
| Interest coverage | — | — | −3.8x | 0.6x | −3.0x |
| Returns and quality | |||||
| Return on capital | — | — | −167.0% | — | — |
| Return on equity | −77.4% | −359.2% | — | — | −65.8% |
| Return on tangible equity | −110.0% | — | — | — | −27.5% |
| Piotroski F-score | — | 1 | 2 | 6 | 0 |
| Altman Z'' | −22.7 | −24.9 | −25.4 | −10.2 | −4.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$11.9M
8 insiders
Of sales under plans
17%
$2.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Fennec Pharmaceuticals Inc. · FENC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.08 a share, the company is worth $367M.
Source: SEC EDGAR XBRL filings (CIK 0001211583). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.